IMBLISY Trademark

Trademark Overview


On Monday, November 2, 2020, a trademark application was filed for IMBLISY with the United States Patent and Trademark Office. The USPTO has given the IMBLISY trademark a serial number of 90294016. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 15, 2024. This trademark is owned by Eli Lilly and Company. The IMBLISY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
imblisy

General Information


Serial Number90294016
Word MarkIMBLISY
Filing DateMonday, November 2, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 13, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 30, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, November 5, 2020NEW APPLICATION ENTERED
Saturday, March 6, 2021ASSIGNED TO EXAMINER
Tuesday, March 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 30, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 13, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 13, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 8, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 18, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, November 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 18, 2021SOU EXTENSION 1 FILED
Saturday, November 27, 2021SOU EXTENSION 1 GRANTED
Friday, November 26, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 18, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, May 18, 2022SOU EXTENSION 2 FILED
Wednesday, May 18, 2022SOU EXTENSION 2 GRANTED
Wednesday, October 26, 2022ASSIGNED TO EXAMINER
Wednesday, May 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU EXTENSION 5 FILED
Wednesday, November 23, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 23, 2022SOU EXTENSION 3 FILED
Wednesday, November 23, 2022SOU EXTENSION 3 GRANTED
Friday, November 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 15, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 15, 2023SOU EXTENSION 4 FILED
Monday, May 15, 2023SOU EXTENSION 4 GRANTED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 14, 2023SOU EXTENSION 5 GRANTED
Monday, July 15, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, July 15, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED